Mai-Britt Zocca
Fondatore presso IO BIOTECH, INC.
Patrimonio netto: 75 486 $ in data 31/05/2024
Provenienza dei contatti di primo grado di Mai-Britt Zocca
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 24 | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark.
9
| Private Company | Miscellaneous Commercial Services | 9 |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.
9
| Subsidiary | Biotechnology | 9 |
Valo Therapeutics Oy
 Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020.
7
| Holding Company | Pharmaceuticals: Major | 7 |
OncoNOx ApS
 OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Cobis A/S
 Cobis A/S Miscellaneous Commercial ServicesCommercial Services Cobis A/S provides business support services.
2
| Private Company | Miscellaneous Commercial Services | 2 |
LevOss ApS
 LevOss ApS BiotechnologyHealth Technology LevOss ApS provides implant device for treatment of musculoskeletal. Its technology is based on mechanotransduction for tissue regeneration. The firm provides solutions for the treatment of bone defects. The company was founded by Jens Vinge Nygaard, Flemming Besenbacher, Cody Bünger, and Lea Bjerre Hokland and is headquartered in Copenhagen, Denmark.
1
| Extinct | Biotechnology | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Mai-Britt Zocca tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Treasurer | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Miscellaneous Commercial Services | Founder President | |
| CODEXIS, INC. | Chemicals: Specialty | Director/Board Member Director/Board Member | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| BIOPORTO A/S | Medical Specialties | Director/Board Member Director/Board Member | |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Aarhus | College/University | Undergraduate Degree Doctorate Degree | |
Symbion A/S
 Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | General Government | Chief Executive Officer Chairman | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree Undergraduate Degree Graduate Degree Graduate Degree | |
| University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| University of Catania | College/University | Corporate Officer/Principal Doctorate Degree | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal Director/Board Member | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor Director of Investments | |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IT-Væksthus A/S | Director/Board Member Chairman | ||
| Dartmouth Medical School | College/University | Doctorate Degree | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| K/S Asschenfeldt, The Pentagon, Derby | Director/Board Member | ||
iSD Immunotech ApS
 iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| COHERUS BIOSCIENCES, INC. | Pharmaceuticals: Major | Human Resources Officer | |
| FOLLICUM AB (PUBL) | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Accelerace Management A/S
 Accelerace Management A/S Investment ManagersFinance Accelerace Management A/S (Accelerace) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was established in 2008 and is owned by a group of institutional investors. | Investment Managers | Director/Board Member Private Equity Investor | |
| Kellogg School of Management | College/University | Masters Business Admin Masters Business Admin | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Director/Board Member | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
HepaRegeniX GmbH
 HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
AFYX Therapeutics AS
 AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Chief Investment Officer Corporate Officer/Principal | |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Chairman | |
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Pharmaceuticals: Major | Founder Director/Board Member | |
| Symbion Fonden | Director/Board Member Director/Board Member | ||
| ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer |
Statistiche
Distribuzione geografica
| Danimarca | 32 |
| Stati Uniti | 15 |
| Italia | 2 |
| Svezia | 2 |
| Finlandia | 2 |
Settori
| Health Technology | 29 |
| Finance | 7 |
| Consumer Services | 7 |
| Commercial Services | 5 |
| Process Industries | 2 |
Posizioni
| Director/Board Member | 258 |
| Corporate Officer/Principal | 84 |
| Chairman | 72 |
| Chief Executive Officer | 59 |
| Independent Dir/Board Member | 43 |
Contatti più connessi
| Insiders | |
|---|---|
| Jørgen Vilhelm Bardenfleth | 64 |
| Claus Asbjørn Andersson | 41 |
| Jack Nielsen | 38 |
| Peter Buhl Jensen | 32 |
| Stephan Christgau | 29 |
| Anthony Giovinazzo | 22 |
| Emmanuelle Coutanceau | 21 |
| Søren Møller | 21 |
| Peter Nordkild | 20 |
| Jón Ingi Benediktsson | 19 |
| K. Hirth | 18 |
| David Smith | 17 |
| Hans Schambye | 16 |
| Alejandra Maria Mørk | 15 |
| Britt Meelby Jensen | 15 |
- Borsa valori
- Insiders
- Mai-Britt Zocca
- Connessioni Società
